Health Care & Life Sciences » Biotechnology | Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
57.99 M
Public Float
29.05 M
Agios Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$5.99
Market Cap
$2.69 B
Shares Outstanding
58.71 M
Public Float
50.88 M

Profile

Address
88 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.agios.com
Updated 07/08/2019
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. Its product candidates include IDHIFA, ivosidenib, AG-881, AG-348, and AG-270.

Financials

View All
Created with Highcharts 5.0.14Agios Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.39 40739 40753 50453 504117 732117 732198 471198 471314 670314 670346 028346 0282013201420152016201720180100k200k300k400k
Created with Highcharts 5.0.14Agios Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.25 54825 54865 35865 35859 11959 11969 89269 89243 01143 01194 38794 387201320142015201620172018025k50k75k100k

John M. Maraganore
Chairman
David T. Scadden
Independent Director